Baseline serum C‐reactive protein and death from colorectal cancer in the NHANES III cohort
Several prospective studies suggest that C‐reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC), whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50–85 years) in the U.S. National...
Saved in:
| Published in | International journal of cancer Vol. 134; no. 8; pp. 1862 - 1870 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken, NJ
Wiley-Blackwell
15.04.2014
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0020-7136 1097-0215 1097-0215 |
| DOI | 10.1002/ijc.28504 |
Cover
| Abstract | Several prospective studies suggest that C‐reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC), whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50–85 years) in the U.S. National Health and Nutrition Examination Survey III (1988–1994), a nationally representative cohort (n = 33,994; 2 months–85 years) with vital status follow‐up to 2000. Hazard ratios (HRs) for mortality associated with baseline clinically raised (≥1.00 mg/dL) and intermediate (≥0.22–0.99 mg/dL) CRP levels were estimated using Cox proportional hazards regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from other obesity‐related cancers (other‐ORCs) and 1,130 from cardiovascular disease (CVD). Participants with clinically raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs = 2.36–2.47) in comparison to persons with undetected levels. HRs were lower for death from other‐ORC and CVD (1.82, 95% CI 1.05–3.15; 1.53, 95% CI 1.29–1.81, respectively). Intermediate CRP level was associated with a nonsignificant 10–21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96–4.87, p = 0.06) compared to those who were overweight (1.22, 95% CI 0.53–2.78) or obese (1.23, 95% CI, 0.37–4.08). A similar pattern was observed for waist circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation.
What's new?
The correlation between C‐Reactive Protein (CRP) and risk of colorectal cancer (CRC) has been unclear. In this study, the authors analyzed data from the long‐term NHANES III survey in order to clarify this association. They found that high levels of serum CRP more than doubled the risk of death from CRC. Surprisingly, this risk was much higher among subjects with a normal BMI than among those who were obese. These results indicate that elevated serum CRP may reflect underlying colonic inflammation, which could, in turn, aid in clinical assessment of CRC risk. |
|---|---|
| AbstractList | Several prospective studies suggest that C-reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC), whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50-85 years) in the U.S. National Health and Nutrition Examination Survey III (1988-1994), a nationally representative cohort (n = 33,994; 2 months-85 years) with vital status follow-up to 2000. Hazard ratios (HRs) for mortality associated with baseline clinically raised (≥1.00 mg/dL) and intermediate (≥0.22-0.99 mg/dL) CRP levels were estimated using Cox proportional hazards regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from other obesity-related cancers (other-ORCs) and 1,130 from cardiovascular disease (CVD). Participants with clinically raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs = 2.36-2.47) in comparison to persons with undetected levels. HRs were lower for death from other-ORC and CVD (1.82, 95% CI 1.05-3.15; 1.53, 95% CI 1.29-1.81, respectively). Intermediate CRP level was associated with a nonsignificant 10-21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96-4.87, p = 0.06) compared to those who were overweight (1.22, 95% CI 0.53-2.78) or obese (1.23, 95% CI, 0.37-4.08). A similar pattern was observed for waist circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation. What's new? The correlation between C-Reactive Protein (CRP) and risk of colorectal cancer (CRC) has been unclear. In this study, the authors analyzed data from the long-term NHANES III survey in order to clarify this association. They found that high levels of serum CRP more than doubled the risk of death from CRC. Surprisingly, this risk was much higher among subjects with a normal BMI than among those who were obese. These results indicate that elevated serum CRP may reflect underlying colonic inflammation, which could, in turn, aid in clinical assessment of CRC risk. Several prospective studies suggest that C-reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC), whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50-85 years) in the U.S. National Health and Nutrition Examination Survey III (1988-1994), a nationally representative cohort (n = 33,994; 2 months-85 years) with vital status follow-up to 2000. Hazard ratios (HRs) for mortality associated with baseline clinically raised ( greater than or equal to 1.00 mg/dL) and intermediate ( greater than or equal to 0.22-0.99 mg/dL) CRP levels were estimated using Cox proportional hazards regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from other obesity-related cancers (other-ORCs) and 1,130 from cardiovascular disease (CVD). Participants with clinically raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs = 2.36-2.47) in comparison to persons with undetected levels. HRs were lower for death from other-ORC and CVD (1.82, 95% CI 1.05-3.15; 1.53, 95% CI 1.29-1.81, respectively). Intermediate CRP level was associated with a nonsignificant 10-21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96-4.87, p = 0.06) compared to those who were overweight (1.22, 95% CI 0.53-2.78) or obese (1.23, 95% CI, 0.37-4.08). A similar pattern was observed for waist circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation. What's new? The correlation between C-Reactive Protein (CRP) and risk of colorectal cancer (CRC) has been unclear. In this study, the authors analyzed data from the long-term NHANES III survey in order to clarify this association. They found that high levels of serum CRP more than doubled the risk of death from CRC. Surprisingly, this risk was much higher among subjects with a normal BMI than among those who were obese. These results indicate that elevated serum CRP may reflect underlying colonic inflammation, which could, in turn, aid in clinical assessment of CRC risk. Several prospective studies suggest that C-reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC), whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50-85 years) in the U.S. National Health and Nutrition Examination Survey III (1988-1994), a nationally representative cohort (n = 33,994; 2 months-85 years) with vital status follow-up to 2000. Hazard ratios (HRs) for mortality associated with baseline clinically raised (≥1.00 mg/dL) and intermediate (≥0.22-0.99 mg/dL) CRP levels were estimated using Cox proportional hazards regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from other obesity-related cancers (other-ORCs) and 1,130 from cardiovascular disease (CVD). Participants with clinically raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs = 2.36-2.47) in comparison to persons with undetected levels. HRs were lower for death from other-ORC and CVD (1.82, 95% CI 1.05-3.15; 1.53, 95% CI 1.29-1.81, respectively). Intermediate CRP level was associated with a nonsignificant 10-21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96-4.87, p = 0.06) compared to those who were overweight (1.22, 95% CI 0.53-2.78) or obese (1.23, 95% CI, 0.37-4.08). A similar pattern was observed for waist circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation.Several prospective studies suggest that C-reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC), whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50-85 years) in the U.S. National Health and Nutrition Examination Survey III (1988-1994), a nationally representative cohort (n = 33,994; 2 months-85 years) with vital status follow-up to 2000. Hazard ratios (HRs) for mortality associated with baseline clinically raised (≥1.00 mg/dL) and intermediate (≥0.22-0.99 mg/dL) CRP levels were estimated using Cox proportional hazards regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from other obesity-related cancers (other-ORCs) and 1,130 from cardiovascular disease (CVD). Participants with clinically raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs = 2.36-2.47) in comparison to persons with undetected levels. HRs were lower for death from other-ORC and CVD (1.82, 95% CI 1.05-3.15; 1.53, 95% CI 1.29-1.81, respectively). Intermediate CRP level was associated with a nonsignificant 10-21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96-4.87, p = 0.06) compared to those who were overweight (1.22, 95% CI 0.53-2.78) or obese (1.23, 95% CI, 0.37-4.08). A similar pattern was observed for waist circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation. Several prospective studies suggest that C-reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC), whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50-85 years) in the U.S. National Health and Nutrition Examination Survey III (1988-1994), a nationally representative cohort (n = 33,994; 2 months-85 years) with vital status follow-up to 2000. Hazard ratios (HRs) for mortality associated with baseline clinically raised (≥1.00 mg/dL) and intermediate (≥0.22-0.99 mg/dL) CRP levels were estimated using Cox proportional hazards regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from other obesity-related cancers (other-ORCs) and 1,130 from cardiovascular disease (CVD). Participants with clinically raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs = 2.36-2.47) in comparison to persons with undetected levels. HRs were lower for death from other-ORC and CVD (1.82, 95% CI 1.05-3.15; 1.53, 95% CI 1.29-1.81, respectively). Intermediate CRP level was associated with a nonsignificant 10-21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96-4.87, p = 0.06) compared to those who were overweight (1.22, 95% CI 0.53-2.78) or obese (1.23, 95% CI, 0.37-4.08). A similar pattern was observed for waist circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation. Several prospective studies suggest that C‐reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC), whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50–85 years) in the U.S. National Health and Nutrition Examination Survey III (1988–1994), a nationally representative cohort (n = 33,994; 2 months–85 years) with vital status follow‐up to 2000. Hazard ratios (HRs) for mortality associated with baseline clinically raised (≥1.00 mg/dL) and intermediate (≥0.22–0.99 mg/dL) CRP levels were estimated using Cox proportional hazards regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from other obesity‐related cancers (other‐ORCs) and 1,130 from cardiovascular disease (CVD). Participants with clinically raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs = 2.36–2.47) in comparison to persons with undetected levels. HRs were lower for death from other‐ORC and CVD (1.82, 95% CI 1.05–3.15; 1.53, 95% CI 1.29–1.81, respectively). Intermediate CRP level was associated with a nonsignificant 10–21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96–4.87, p = 0.06) compared to those who were overweight (1.22, 95% CI 0.53–2.78) or obese (1.23, 95% CI, 0.37–4.08). A similar pattern was observed for waist circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation. What's new? The correlation between C‐Reactive Protein (CRP) and risk of colorectal cancer (CRC) has been unclear. In this study, the authors analyzed data from the long‐term NHANES III survey in order to clarify this association. They found that high levels of serum CRP more than doubled the risk of death from CRC. Surprisingly, this risk was much higher among subjects with a normal BMI than among those who were obese. These results indicate that elevated serum CRP may reflect underlying colonic inflammation, which could, in turn, aid in clinical assessment of CRC risk. |
| Author | Rawal, Shristi Stevens, Richard G. Swede, Helen Hajduk, Alexandra M. Sharma, Jyoti Vella, Anthony T. Rasool, Homaira Tobet, Rebecca E. |
| Author_xml | – sequence: 1 givenname: Helen surname: Swede fullname: Swede, Helen organization: University of Connecticut Health Center – sequence: 2 givenname: Alexandra M. surname: Hajduk fullname: Hajduk, Alexandra M. organization: University of Massachusetts Medical School – sequence: 3 givenname: Jyoti surname: Sharma fullname: Sharma, Jyoti organization: Westchester Medical Center – sequence: 4 givenname: Shristi surname: Rawal fullname: Rawal, Shristi organization: University of Connecticut Health Center – sequence: 5 givenname: Homaira surname: Rasool fullname: Rasool, Homaira organization: University of Connecticut Health Center – sequence: 6 givenname: Anthony T. surname: Vella fullname: Vella, Anthony T. organization: University of Connecticut Health Center – sequence: 7 givenname: Rebecca E. surname: Tobet fullname: Tobet, Rebecca E. organization: University of Connecticut Health Center – sequence: 8 givenname: Richard G. surname: Stevens fullname: Stevens, Richard G. organization: University of Connecticut Health Center |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28222485$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24122448$$D View this record in MEDLINE/PubMed |
| BookMark | eNqN0c1O3DAQB3ALUcFCOfACyBJC6iVgO-PEOcIKSioEB8oRWY4z1maVD7ATEDcegWfsk9QLWyr11JMt_X_yeGZ2yGY_9EjIPmfHnDFx0iztsVCSwQaZcVbkCRNcbpJZzFiS8zTbJjshLBnjPKItsi2ACwGgZuT-zARsmx5pQD91dP7r9c2jsWPzhPTBDyM2PTV9TWs044I6P3TUDu3g0Y6mpdb0Fj2NZlwgvb48vT6_pWVZRrMY_PiVfHGmDbi3PnfJ3cX5z_llcnXzvZyfXiVLYAqSqlBCqaKqlMtd5aQt6qwGmTlrQAmXKoBK5rIqEGrnQMna2QxUmtXKxZynu-Tbx7vxx48ThlF3TbDYtqbHYQo6ti3TFFSe_g8FkBIyGenhP3Q5TL6PjWgOBWS54MWq9sFaTVWHtX7wTWf8i_4z4wiO1sAEa1rn48ya8NcpEZ1alTv5cM9Niy-fOWd6tWQdl6zfl6zLH_P3S_obizuYvw |
| CODEN | IJCNAW |
| ContentType | Journal Article |
| Copyright | 2013 UICC 2015 INIST-CNRS 2013 UICC. |
| Copyright_xml | – notice: 2013 UICC – notice: 2015 INIST-CNRS – notice: 2013 UICC. |
| DBID | IQODW CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. 7X8 7T2 7U1 C1K |
| DOI | 10.1002/ijc.28504 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Health and Safety Science Abstracts (Full archive) Risk Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic Risk Abstracts Health & Safety Science Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitleList | AIDS and Cancer Research Abstracts Risk Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0215 |
| EndPage | 1870 |
| ExternalDocumentID | 3206658311 24122448 28222485 IJC28504 |
| Genre | article Journal Article |
| GeographicLocations | USA |
| GeographicLocations_xml | – name: USA |
| GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT .55 .GJ 31~ 3O- 53G 8WZ A6W AANHP ABEFU ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AGHNM AHEFC AI. ASPBG AVWKF AZFZN BDRZF EX3 FEDTE GLUZI HF~ HVGLF IQODW M6P PALCI SAMSI VH1 WOW X7M Y6R ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 AAMMB AEFGJ AEYWJ AGXDD AGYGG AIDQK AIDYY H94 K9. 7X8 7T2 7U1 C1K |
| ID | FETCH-LOGICAL-j4084-b982889bb8f7fbf5c9d6d456fca482f3844b575b9e4dff485dfc64836d8f82f13 |
| IEDL.DBID | DR2 |
| ISSN | 0020-7136 1097-0215 |
| IngestDate | Fri Jul 11 16:42:56 EDT 2025 Fri Jul 11 06:25:31 EDT 2025 Fri Jul 25 04:07:52 EDT 2025 Thu Apr 03 07:06:30 EDT 2025 Wed Apr 02 07:27:34 EDT 2025 Wed Jan 22 16:55:42 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Rectal disease Adipose tissue C-reactive protein Colorectal cancer anti-inflammatory drugs central adiposity Body mass index Colon cancer Cancerology Adiposity Cohort study Intestinal disease C reactive protein Nutritional status Drug Obesity Mortality Nutrition disorder Antiinflammatory agent Inflammation Malignant tumor Serum protein Colonic disease Acute phase protein Digestive diseases Death neoplasms Cancer colorectal cancer inflammation body mass index colon cancer cancer obesity |
| Language | English |
| License | CC BY 4.0 2013 UICC. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-j4084-b982889bb8f7fbf5c9d6d456fca482f3844b575b9e4dff485dfc64836d8f82f13 |
| Notes | Conflicts of interest Nothing to report Study concept and design (H.S. and A.M.H.); analysis and interpretation of data (H.S., A.M.H., J.S., S.R., A.T.V. and R.G.S.); drafting of manuscript (All); critical revision of manuscript for important intellectual content (All) and statistical analysis (H.S. and A.M.H.) Author contributions ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 24122448 |
| PQID | 1494672191 |
| PQPubID | 105430 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1505334873 proquest_miscellaneous_1504455465 proquest_journals_1494672191 pubmed_primary_24122448 pascalfrancis_primary_28222485 wiley_primary_10_1002_ijc_28504_IJC28504 |
| PublicationCentury | 2000 |
| PublicationDate | 15 April 2014 |
| PublicationDateYYYYMMDD | 2014-04-15 |
| PublicationDate_xml | – month: 04 year: 2014 text: 15 April 2014 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken, NJ |
| PublicationPlace_xml | – name: Hoboken, NJ – name: United States – name: Hoboken |
| PublicationTitle | International journal of cancer |
| PublicationTitleAlternate | Int J Cancer |
| PublicationYear | 2014 |
| Publisher | Wiley-Blackwell Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley-Blackwell – name: Wiley Subscription Services, Inc |
| References | 2012; 61 2001; 344 2005; 293 2009; 20 2005; 352 2004; 28 2006; 55 2006; 17 2008; 16 2006; 15 2008; 9 1998 2008 1996 2008; 57 2006 2008; 4 2009; 373 2008; 123 2012; 367 2005; 28 2010; 61 2012; 30 2005; 46 2005; 69 2004; 10 2009; 11 2005; 142 2004; 291 2006; 24 2010; 138 1999; 19 2006; 66 1999; 282 2000; 108 2008; 68 2010; 172 2008; 87 2007; 61 2013; 132 2011; 48 2005; 15 2009; 3 2012; 7 2012; 22 2001; 357 2009; 15 2005; 14 |
| References_xml | – volume: 123 start-page: 1133 year: 2008 end-page: 40 article-title: C‐reactive protein and colorectal cancer risk: a systematic review of prospective studies publication-title: Int J Cancer – volume: 15 start-page: 690 year: 2006 end-page: 5 article-title: Japan Public Health Center‐Based Prospective Study G. Plasma C‐reactive protein and risk of colorectal cancer in a nested case‐control study: Japan Public Health Center‐based prospective study publication-title: Cancer Epidemiol Biomarkers Prev – volume: 7 start-page: e31131 year: 2012 article-title: Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease publication-title: PloS One – volume: 172 start-page: 407 year: 2010 end-page: 18 article-title: Circulating C‐reactive protein concentrations and risks of colon and rectal cancer: a nested case‐control study within the European Prospective Investigation into Cancer and Nutrition publication-title: Am J Epidemiol – volume: 10 start-page: 661 year: 2004 end-page: 5 article-title: C‐reactive protein as a marker for inflammatory bowel disease publication-title: Inflamm Bowel Dis – volume: 87 start-page: 30 year: 2008 end-page: 5 article-title: A prospective study of weight change and systemic inflammation over 9 y publication-title: Am J Clin Nutr – volume: 20 start-page: 15 year: 2009 end-page: 26 article-title: Associations of circulating C‐reactive protein and interleukin‐6 with cancer risk: findings from two prospective cohorts and a meta‐analysis publication-title: Cancer Causes Control – volume: 16 start-page: 875 year: 2008 end-page: 80 article-title: Obesity, and C‐reactive protein levels among White, Black, and Hispanic US adults publication-title: Obesity – year: 2006 article-title: Linked mortality file: detailed notes for selected variables publication-title: National Center for Health Statistics – volume: 282 start-page: 2131 year: 1999 end-page: 5 article-title: Elevated C‐reactive protein levels in overweight and obese adults publication-title: JAMA – volume: 373 start-page: 1301 year: 2009 end-page: 9 article-title: Aspirin, salicylates, and cancer publication-title: Lancet – volume: 15 start-page: 381 year: 2006 end-page: 4 article-title: Plasma C‐reactive protein and risk of cancer: a prospective study from Greece publication-title: Cancer Epidemiol Biomarkers Prev – volume: 28 start-page: 410 year: 2004 end-page: 15 article-title: Serum levels of interleukin‐6 and C‐reactive protein correlate with body mass index across the broad range of obesity publication-title: J Parenter Enteral Nutr – volume: 22 start-page: 112 year: 2012 end-page: 19 article-title: Prescription medication use among normal weight, overweight, and obese adults, United States, 2005‐2008 publication-title: Ann Epidemiol – volume: 14 start-page: 2413 year: 2005 end-page: 18 article-title: Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort publication-title: Cancer Epidemiol Biomarkers Prev – year: 2008 – volume: 28 start-page: 187 year: 2005 end-page: 96 article-title: Involvement of IL‐6 in the pathogenesis of inflammatory bowel disease and colon cancer publication-title: Clin Rev Allergy Immunol – volume: 15 start-page: 103 year: 2009 end-page: 13 article-title: IL‐6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis‐associated cancer publication-title: Cancer Cell – volume: 57 start-page: 1181 year: 2008 end-page: 9 article-title: Associations of visceral adiposity and exercise participation with C‐reactive protein, insulin resistance, and endothelial dysfunction in Korean healthy adults publication-title: Metabolism – volume: 3 start-page: 309 year: 2009 end-page: 15 article-title: The Jupiter study, CRP screening, and aggressive statin therapy‐implications for the primary prevention of cardiovascular disease publication-title: Ther Adv Cardiovasc Dis – volume: 108 start-page: 496 year: 2000 end-page: 9 article-title: Use of cholesterol‐lowering medications in the United States from 1991 to 1997 publication-title: Am J Med – volume: 30 start-page: 12 year: 2012 end-page: 18 article-title: Biomarkers in diverticular diseases of the colon publication-title: Dig Dis – volume: 142 start-page: 425 year: 2005 end-page: 32 article-title: C‐reactive protein levels are not associated with increased risk for colorectal cancer in women publication-title: Ann Intern Med – volume: 357 start-page: 539 year: 2001 end-page: 45 article-title: Inflammation and cancer: back to Virchow? publication-title: Lancet – volume: 19 start-page: 972 year: 1999 end-page: 8 article-title: C‐reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue publication-title: Arterioscler Thromb Vasc Biol – volume: 138 start-page: 2101 year: 2010 end-page: 2114.e5 article-title: Inflammation and colon cancer publication-title: Gastroenterology – volume: 367 start-page: 1596 year: 2012 end-page: 606 article-title: Aspirin use, tumor PIK3CA mutation, and colorectal‐cancer survival publication-title: N Engl J Med – volume: 291 start-page: 585 year: 2004 end-page: 90 article-title: C‐reactive protein and the risk of incident colorectal cancer publication-title: JAMA – start-page: 98 year: 1998 end-page: 4083 article-title: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report publication-title: National Heart Lung and Blood Institute – year: 1996 – volume: 4 start-page: 379 year: 2008 end-page: 90 article-title: C‐reactive protein at the interface between innate immunity and inflammation publication-title: Expert Rev Clin Immunol – volume: 55 start-page: 285 year: 2006 end-page: 91 article-title: Influence of obesity on the risk of developing colon cancer publication-title: Gut – volume: 132 start-page: 2648 year: 2013 end-page: 58 article-title: Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers publication-title: Int J Cancer – volume: 15 start-page: S185 issue: Suppl 2 year: 2005 end-page: S189 article-title: Colorectal cancer and serum C‐reactive protein levels: a case‐control study nested in the JACC Study publication-title: J Epidemiol – volume: 68 start-page: 323 year: 2008 end-page: 8 article-title: Circulating levels of inflammatory cytokines and risk of colorectal adenomas publication-title: Cancer Res – volume: 17 start-page: 145 year: 2006 end-page: 56 article-title: Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes publication-title: J Nutr Biochem – volume: 293 start-page: 1868 year: 2005 end-page: 74 article-title: Secular trends in cardiovascular disease risk factors according to body mass index in US adults publication-title: JAMA – volume: 66 start-page: 2483 year: 2006 end-page: 7 article-title: A prospective study of serum C‐reactive protein and colorectal cancer risk in men publication-title: Cancer Res – volume: 352 start-page: 20 year: 2005 end-page: 8 article-title: Pravastatin or Atorvastatin E, Infection Therapy‐Thrombolysis in Myocardial Infarction I. C‐reactive protein levels and outcomes after statin therapy publication-title: N Engl J Med – volume: 61 start-page: 824 year: 2007 end-page: 33 article-title: A systematic review of the association between circulating concentrations of C reactive protein and cancer publication-title: J Epidemiol Community Health – volume: 48 start-page: 155 year: 2011 end-page: 70 article-title: Elevated C‐reactive protein in the diagnosis, prognosis, and cause of cancer publication-title: Crit Rev Clin Lab Sci – volume: 61 start-page: 301 year: 2010 end-page: 16 article-title: Biological mechanisms linking obesity and cancer risk: new perspectives publication-title: Annu Rev Med – volume: 24 start-page: 5216 year: 2006 end-page: 22 article-title: C‐reactive protein levels, variation in the C‐reactive protein gene, and cancer risk: the Rotterdam Study publication-title: J Clin Oncol – volume: 11 start-page: 488 year: 2009 end-page: 95 article-title: Diagnostic advances in inflammatory bowel disease (imaging and laboratory publication-title: Curr Gastroenterol Rep – volume: 9 start-page: 450 year: 2008 end-page: 60 article-title: The role of adiposity as a determinant of an inflammatory milieu publication-title: J Cardiovasc Med – volume: 344 start-page: 1959 year: 2001 end-page: 65 article-title: Air Force/Texas Coronary Atherosclerosis Prevention Study I. Measurement of C‐reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events publication-title: N Engl J Med – volume: 61 start-page: 78 year: 2012 end-page: 85 article-title: Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease publication-title: Gut – volume: 46 start-page: 1112 year: 2005 end-page: 13 article-title: Release of C‐reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation publication-title: J Am Coll Cardiol – volume: 69 start-page: 29 year: 2005 end-page: 35 article-title: Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF‐α and IL‐6 publication-title: Diabetes Res Clin Pract |
| SSID | ssj0011504 |
| Score | 2.2793052 |
| Snippet | Several prospective studies suggest that C‐reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer... Several prospective studies suggest that C-reactive protein (CRP), a nonspecific serologic marker of inflammation, might be linked to risk of colorectal cancer... |
| SourceID | proquest pubmed pascalfrancis wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1862 |
| SubjectTerms | Aged Aged, 80 and over anti‐inflammatory drugs Biological and medical sciences Biomarkers, Tumor - blood body mass index Body Weight C-Reactive Protein - analysis Cancer Cardiovascular Diseases - blood Cardiovascular Diseases - mortality central adiposity Cohort Studies colon cancer Colorectal cancer Colorectal Neoplasms - blood Colorectal Neoplasms - metabolism Colorectal Neoplasms - mortality Cross-Sectional Studies C‐reactive protein Female Gastroenterology. Liver. Pancreas. Abdomen Health risk assessment Humans Inflammation Inflammation - blood Male Medical research Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) neoplasms Nutrition Surveys obesity Obesity - metabolism Prospective Studies Proteins Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Treatment Outcome Tumors Waist Circumference |
| Title | Baseline serum C‐reactive protein and death from colorectal cancer in the NHANES III cohort |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.28504 https://www.ncbi.nlm.nih.gov/pubmed/24122448 https://www.proquest.com/docview/1494672191 https://www.proquest.com/docview/1504455465 https://www.proquest.com/docview/1505334873 |
| Volume | 134 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1LS-wwFMcP4kLc-PY6vojgwk3HPtI0xZWOyozgLHyAi3spTdKAilXmsXHlR_Az-kk8J-1UFLmIu0IyQ5pzcuafyTm_AOxGlgc6JPRlKo3HbSy8tJDcU4GyWsVca0GFwud90b3mZzfxzRQcTGphKj5E84cbrQwXr2mB52q4_wENvb3T7VDGjgUaRIK4-ccXDTqKhE5NYPY93IiJCVXID_ebT1IiZD7EubDVJRbfqczPotX96pzOw9_JeKtkk_v2eKTa-vkLyvGXL7QAc7UaZYeV-yzCVFEuwcx5fd6-DP-OclewXjD01PED67y9vKLKdDGSOcTDbcny0jBDSpJRrQojDDaFUfxeTS41YNgHZSbrdw_7J5es1-sxupZ3MFqB69OTq07Xqy9k8O64TwZMcX8mU6WkTayysU6NMKjALKHRQxtJzhXKP5UW3FjLZWysFlxGwkiL7UG0CtPlY1msATPEeZM2TwwqIGtSlWg_ML4xWiVChbIF259Mkz1V8I2M0l4Jw9aCzYmtsnrZDXEfk2LgxyActGCnacYFQ6cgeVk8jrEPzjCn3Lz4v31ciXISteBP5QcfA-B0GMlxhHvOmk1DBYAOM7Rj5uyY9c467mH95103YBYlmcsNCuJNmB4NxsUWyp6R2nb-_Q546_3D |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB5VQQIuUN6hISwSBy5O_Fjba6mXNLSKQ5MDpFIukeXd9UotwkF5XDj1J_Q39pd0Zu04KkIIcbO0Y2vtefjbnZlvAT4GhnvKJ-rLRGiHmzBykkJwR3rSKBlypSJqFJ5Mo9EFH8_D-QEc73phKn6IZsONPMPGa3Jw2pDu71lDL69UzxchkYE-oPwcueXnrw15FEGdmoPZdXApFu14hVy_39xKpZD5Gr-GqY6x-BPOvA9b7X_n7CksdjOuyk2-97Yb2VO_fiNz_N9XOoQnNSBlg8qCnsFBUT6Hh5M65f4CFie57VkvGBrr9gcb3l7fINC0YZJZlofLkuWlZprAJKN2FUZM2BRJ8bmKrGrFUAaRJpuOBtPTbyxNU0Yn8642L-Hi7HQ2HDn1mQzOFXdJhwku0UQipTCxkSZUiY40gjBD7Oi-CQTnEhGgTAqujeEi1EZFXASRFgbHveAVtMplWbwBponqTZg81giCjE5krFxPu1orGUfSF23o3tNN9rPi38io8pWY2NrQ2Skrqz1vjUuZBGM_xmGvDR-aYfQZSoTkZbHcogx-YU7leeFfZWyXchy04XVlCPsJcMpHcpzhJ6vOZqDigPYz1GNm9Zil46G9ePvvou_h0Wg2Oc_O0-mXI3iMCM2WCnlhB1qb1bZ4hyhoI7vW2O8AUXEB7w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hkFAvLa-22_IwUg9csuThOI44wcJqw2NVlSJxaBXFdiwBIqBl99JTfwK_kV_CjJMNAiFU9RbJk8jxPPJNPPMZ4FtkeaBDor5MpfG4jYWXlpJ7KlBWq5hrLahR-GQoBmf88Dw-n4GdaS9MzQ_R_nAjz3Dxmhz81tjtJ9LQi0vdDWVMXKBzXGB2RYjoR8sdRUinoWD2PczExJRWyA-321upErK4w8Ww9SkWr8HM56jVfXb6H-DXdMJ1tclVdzJWXf3nBZfjf77RArxv4Cjbre1nEWbKagnmT5oN92X4vVe4jvWSoalOrlnv4e89wkwXJJnjeLioWFEZZghKMmpWYcSDTXEUn6vJpkYMZRBnsuFgd3hwyrIsY3Qu72i8Amf9g5-9gdecyOBdcp80mGKCJlOlpE2ssrFOjTAIwSxxo4c2kpwrxH8qLbmxlsvYWC24jISRFseD6CPMVjdV-RmYIaI3aYvEIASyJlWJ9gPjG6NVIlQoO7D-TDX5bc2-kVPdK_GwdWB1qqu88bs7TGRSjPwYhYMObLbD6DG0DVJU5c0EZXCFORXnxW_KuB7lJOrAp9oOnibAaTeS4wy3nDbbgZoBOsxRj7nTY54d9tzFl38X3YD57_v9_DgbHn2FdwjPXJ1QEK_C7Hg0KdcQAo3VujP1R0_dAJ4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Baseline+serum+C-reactive+protein+and+death+from+colorectal+cancer+in+the+NHANES+III+cohort&rft.jtitle=International+journal+of+cancer&rft.au=SWEDE%2C+Helen&rft.au=HAJDUK%2C+Alexandra+M&rft.au=SHARMA%2C+Jyoti&rft.au=RAWAL%2C+Shristi&rft.date=2014-04-15&rft.pub=Wiley-Blackwell&rft.issn=0020-7136&rft.volume=134&rft.issue=8&rft.spage=1862&rft.epage=1870&rft_id=info:doi/10.1002%2Fijc.28504&rft.externalDBID=n%2Fa&rft.externalDocID=28222485 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon |